共 50 条
Structural Predictors of Lung Function Decline in Young Smokers with Normal Spirometry
被引:14
|作者:
Ritchie, Andrew I.
[1
,2
]
Donaldson, Gavin C.
[1
]
Hoffman, Eric A.
[3
,4
]
Allinson, James P.
[1
,5
]
Bloom, Chloe I.
[1
]
Bolton, Charlotte E.
[6
,7
,8
]
Choudhury, Gourab
[9
]
Gerard, Sarah E.
[4
]
Guo, Junfeng
Alves-Moreira, Luana
[1
]
McGarvey, Lorcan
[10
,11
]
Sapey, Elizabeth
[12
]
Stockley, Robert A.
[12
]
Yip, K. P.
[12
]
Singh, Dave
[13
]
Wilkinson, Tom
[14
,15
]
Fageras, Malin
[16
]
Ostridge, Kristoffer
[14
,16
]
Joens, Olaf
[17
]
Bucchioni, Enrica
[18
]
Compton, Chris H.
[19
]
Jones, Paul
[19
]
Mezzi, Karen
[20
]
Vestbo, Jorgen
[13
]
Calverley, Peter M. A.
[21
]
Wedzicha, Jadwiga A.
[1
]
机构:
[1] Imperial Coll London, Natl Heart & Lung Inst, London, England
[2] AstraZeneca, Cambridge, England
[3] Univ Iowa, Dept Radiol, Iowa City, IA USA
[4] Univ Iowa, Roy J Carver Dept Biomed Engn Med & Biomed Engn, Iowa City, IA USA
[5] Royal Brompton Hosp, London, England
[6] Univ Nottingham, NIHR Nottingham Biomed Res Ctr, Nottingham, England
[7] Univ Nottingham, Ctr Resp Res, NIHR Nottingham, Translat Med Sci,Sch Med, Nottingham, England
[8] Queens Med Res Inst, ELEGI Labs, Edinburgh, Midlothian, Scotland
[9] Queens Med Res Inst, COLT Labs, Edinburgh, Midlothian, Scotland
[10] Queens Univ Belfast, Wellcome Wolfson Inst Expt Med, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland
[11] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland
[12] Univ Birmingham, Inst Inflammat & Ageing, Birmingham, W Midlands, England
[13] Univ Manchester, Div Infect Immun & Resp Med, Manchester, Lancs, England
[14] Univ Southampton, Fac Med, Southampton, Hants, England
[15] Southampton Univ Hosp, Natl Inst Hlth & Care Res, Southampton Biomed Res Ctr, Southampton, Hants, England
[16] AstraZeneca, Gothenburg, Sweden
[17] Boehringer Ingelheim Int GmbH, Ingelheim, Germany
[18] Chiesi Farmaceut SpA, Parma, Italy
[19] GlaxoSmithKline, Brentford, England
[20] Novartis Pharma AG, Basel, Switzerland
[21] Univ Liverpool, Inst Life Course & Med Sci, Liverpool, Merseyside, England
基金:
美国国家卫生研究院;
关键词:
chronic obstructive pulmonary disease;
early COPD;
FEV1;
lung function;
quantitative computed tomography;
AIR-FLOW OBSTRUCTION;
CHRONIC MUCUS HYPERSECRETION;
COMPUTED-TOMOGRAPHY;
NATURAL-HISTORY;
DISEASE;
EMPHYSEMA;
STANDARDIZATION;
ASSOCIATION;
PHENOTYPE;
UPDATE;
D O I:
10.1164/rccm.202307-1203OC
中图分类号:
R4 [临床医学];
学科分类号:
1002 ;
100602 ;
摘要:
Rationale: Chronic obstructive pulmonary disease (COPD) due to tobacco smoking commonly presents when extensive lung damage has occurred. Objectives: We hypothesized that structural change would be detected early in the natural history of COPD and would relate to loss of lung function with time. Methods: We recruited 431 current smokers (median age, 39 yr; 16 pack-years smoked) and recorded symptoms using the COPD Assessment Test (CAT), spirometry, and quantitative thoracic computed tomography (QCT) scans at study entry. These scan results were compared with those from 67 never-smoking control subjects. Three hundred sixty-eight participants were followed every six months with measurement of postbronchodilator spirometry for a median of 32months. The rate of FEV1 decline, adjusted for current smoking status, age, and sex, was related to the initial QCT appearances and symptoms, measured using the CAT. Measurements and Main Results: There were no material differences in demography or subjective CT appearances between the young smokers and control subjects, but 55.7% of the former had CAT scores greater than 10, and 24.2% reported chronic bronchitis. QCT assessments of disease probability-defined functional small airway disease, ground-glass opacification, bronchovascular prominence, and ratio of small blood vessel volume to total pulmonary vessel volume were increased compared with control subjects and were all associated with a faster FEV1 decline, as was a higher CAT score. Conclusions: Radiological abnormalities on CT are already established in young smokers with normal lung function and are associated with FEV1 loss independently of the impact of symptoms. Structural abnormalities are present early in the natural history of COPD and are markers of disease progression.
引用
收藏
页码:1208 / 1218
页数:11
相关论文